<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Tositumomab</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Tositumomab">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Tositumomab</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Tositumomab</b> is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell.<span class="mw-ref" id="cite_ref-GSK_FDA_Label_1-0"><a href="#cite_note-GSK_FDA_Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, <b>Iodine-131 Tositumomab</b> (branded as <b>Bexxar</b>), for the treatment of non-Hodgkins lymphoma.<span class="mw-ref" id="cite_ref-GSK_FDA_Label_1-1"><a href="#cite_note-GSK_FDA_Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It is classified as a IgG2a lambda antibody.<span class="mw-ref" id="cite_ref-GSK_FDA_Label_1-2"><a href="#cite_note-GSK_FDA_Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Tositumomab</span></caption><tbody><tr><th colspan="2" style="text-align:center;background:#ddd">Monoclonal antibody</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Type</th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Source</th><td>Mouse</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Target</th><td>CD20</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Bexxar</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/tositumomab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/tositumomab.html'" tppabs="https://www.drugs.com/monograph/tositumomab.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a609013.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a609013.html'" tppabs="https://medlineplus.gov/druginfo/meds/a609013.html" class="external text external">a609013</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>V10XA53<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=V10XA53  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=V10XA53'" tppabs="https://www.whocc.no/atc_ddd_index/?code=V10XA53" class="external text external">WHO</a></span>)<span> </span>(sequential regimen with <sup>131</sup>I form)</li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=208921-02-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=208921-02-2'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=208921-02-2" class="external text external">208921-02-2</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00081  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00081'" tppabs="https://www.drugbank.ca/drugs/DB00081" class="external text external">DB00081</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=0343IGH41U  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=0343IGH41U'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=0343IGH41U" class="external text external">0343IGH41U</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D08622  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D08622'" tppabs="https://www.kegg.jp/entry/D08622" class="external text external">D08622</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201604  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201604'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201604" class="external text external">ChEMBL1201604</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>6416</sub><span>H</span><sub>9874</sub><span>N</span><sub>1688</sub><span>O</span><sub>1987</sub><span>S</span><sub>44</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">143<span style="margin-left:.25em;">860</span>.04</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470611959&page2=Tositumomab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470611959&page2=Tositumomab'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470611959&page2=Tositumomab" class="external text external">(verify)</a></span></span></td></tr></tbody></table>
<p>The drug combination was developed by Corixa which was purchased by GlaxoSmithKline in 2005.<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It was sold for about $25,000 for one round of treatment.<span class="mw-ref" id="cite_ref-Srinivasan2011rev_4-0"><a href="#cite_note-Srinivasan2011rev-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> Bexxar competed with Zevalin,<span class="mw-ref" id="cite_ref-Davies07_5-0"><a href="#cite_note-Davies07-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> until the former's discontinuation in 2014.<span class="mw-ref" id="cite_ref-Timmerman2013_6-0"><a href="#cite_note-Timmerman2013-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Clinical_use">Clinical use</h2></summary>
    

<p>A personalized regimen using Bexxar was approved for the treatment of relapsed or chemotherapy/<a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituxan" title="Rituxan" class="mw-redirect">rituxan</a>-refractory Non-Hodgkin lymphoma in 2003.<span class="mw-ref" id="cite_ref-Srinivasan2011rev_4-1"><a href="#cite_note-Srinivasan2011rev-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-FDAapproval_8-0"><a href="#cite_note-FDAapproval-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>

<p>The radioactive dose was adjusted for each patient in order to maximize the radiation delivered to the tumor and minimize the exposure of other organs.<span class="mw-ref" id="cite_ref-GSK_FDA_Label_1-3"><a href="#cite_note-GSK_FDA_Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-2002Descrip_9-0"><a href="#cite_note-2002Descrip-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><sup class="reference" style="white-space:nowrap;">:<span>14–15</span></sup> Bexxar combined separate administration of unlabelled and iodine-labelled (i.e. covalently bonded to <sup>131</sup>I) tositumomab. A first dose of labelled antibody was given once, and whole-body radiation was measured with a gamma camera over seven days.  Analysis of that imaging data allowed an optimal dose of labelled antibody to be calculated, which was then administered once a day, for up to seven days.<span class="mw-ref" id="cite_ref-GSK_FDA_Label_1-4"><a href="#cite_note-GSK_FDA_Label-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-2002Descrip_9-1"><a href="#cite_note-2002Descrip-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><sup class="reference" style="white-space:nowrap;">:<span>14–15</span></sup>  Each time the labelled antibody was administered, it was always preceded by unlabelled (non-radioactive) antibody. Early clinical trials had shown that total body residence times of radioactivity were longer in people who first received unlabelled antibody, so that a lower dose of labelled antibody was needed to deliver the required total dose of radiation; additionally labelled antibody targeted tumors better in people pre-treated with unlabelled antibody.<span class="mw-ref" id="cite_ref-2002Descrip_9-2"><a href="#cite_note-2002Descrip-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><sup class="reference" style="white-space:nowrap;">:<span>21</span></sup></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Availability">Availability</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="United_States">United States</h3></summary>
    
<p>Following a first investigational new drug application in 1989 and biologics license application in 2000, Bexxar was approved by the FDA in 2003.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-FDAapproval_8-1"><a href="#cite_note-FDAapproval-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> Sale of Bexxar was discontinued and marketing approval was withdrawn in February 2014 due to a decline in usage (fewer than 75 patients in 2012). One possible explanation for the lack of demand, despite a claimed 70% response rate, was that oncologists could not sell it directly to patients but had to refer patients to third party specialist centers, however a "muddled clinical trials strategy", supply chain issues, reimbursement problems, and emergence of non-radioactive competitors has also been blamed.<span class="mw-ref" id="cite_ref-Timmerman2013_6-1"><a href="#cite_note-Timmerman2013-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Davies07_5-1"><a href="#cite_note-Davies07-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Europe">Europe</h3></summary>
    
<p>The European Medicines Agency granted tositumomab and <sup>131</sup>I-tositumomab orphan drug status, for the treatment of follicular lymphoma, to Amersham plc  in 2003. This was withdrawn in October 2015 at the request of the new owner, GlaxoSmithKline.<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-GSK_FDA_Label-1"> <span id="mw-reference-text-cite_note-GSK_FDA_Label-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125011s0126lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125011s0126lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125011s0126lbl.pdf" class="external text external">"BEXXAR drug label"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>. GlaxoSmithKline. August 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">18 January</span> 2016</span>.</cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.abcam.com/protocols/antibody-structure-and-isotypes  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.abcam.com/protocols/antibody-structure-and-isotypes'" tppabs="https://www.abcam.com/protocols/antibody-structure-and-isotypes" class="external text external">"Guide to Antibody structure and isotypes"</a>. <i>Abcam</i><span class="reference-accessdate">. Retrieved <span class="nowrap">25 July</span> 2020</span>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite id="CITEREFMozee2005" class="citation news cs1">Mozee, Carla (29 April 2005). <a href="javascript:if(confirm('https://www.marketwatch.com/story/corixa-agrees-to-glaxo-acquisition-for-300-million  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.marketwatch.com/story/corixa-agrees-to-glaxo-acquisition-for-300-million'" tppabs="https://www.marketwatch.com/story/corixa-agrees-to-glaxo-acquisition-for-300-million" class="external text external">"Glaxo to acquire Corixa for $300 million"</a>. <i>MarketWatch</i>.</cite></span></li><li id="cite_note-Srinivasan2011rev-4"> <span id="mw-reference-text-cite_note-Srinivasan2011rev-4" class="mw-reference-text"><cite id="CITEREFSrinivasanMukherji2011" class="citation journal cs1">Srinivasan A, Mukherji SK (April 2011). <a href="javascript:if(confirm('https://doi.org/10.3174/ajnr.A2593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3174/ajnr.A2593'" tppabs="https://doi.org/10.3174/ajnr.A2593" class="external text external">"Tositumomab and iodine I 131 tositumomab (Bexaar)"</a>. <i>AJNR. American Journal of Neuroradiology</i>. <b>32</b> (4): 637–8. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.3174%2Fajnr.A2593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3174%2Fajnr.A2593'" tppabs="https://doi.org/10.3174%2Fajnr.A2593" class="external text external">10.3174/ajnr.A2593</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21436340  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21436340'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21436340" class="external text external">21436340</a>.</cite></span></li><li id="cite_note-Davies07-5"> <span id="mw-reference-text-cite_note-Davies07-5" class="mw-reference-text"><cite id="CITEREFDavies2007" class="citation journal cs1">Davies, A J (28 May 2007). <a href="javascript:if(confirm('https://doi.org/10.1038/sj.onc.1210378  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/sj.onc.1210378'" tppabs="https://doi.org/10.1038/sj.onc.1210378" class="external text external">"Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab"</a>. <i>Oncogene</i>. <b>26</b> (25): 3614–3628. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.onc.1210378  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.onc.1210378'" tppabs="https://doi.org/10.1038%2Fsj.onc.1210378" class="external text external">10.1038/sj.onc.1210378</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17530015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17530015'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17530015" class="external text external">17530015</a>.</cite></span></li><li id="cite_note-Timmerman2013-6"> <span id="mw-reference-text-cite_note-Timmerman2013-6" class="mw-reference-text"><cite id="CITEREFTimmerman2013" class="citation news cs1">Timmerman, Luke (26 August 2013). <a href="javascript:if(confirm('http://www.xconomy.com/national/2013/08/26/why-good-drugs-sometimes-fail-in-the-market-the-bexxar-story/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.xconomy.com/national/2013/08/26/why-good-drugs-sometimes-fail-in-the-market-the-bexxar-story/'" tppabs="http://www.xconomy.com/national/2013/08/26/why-good-drugs-sometimes-fail-in-the-market-the-bexxar-story/" class="external text external">"Why Good Drugs Sometimes Fail: The Bexxar Story"</a>. <i>Xconomy</i>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html'" tppabs="https://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html" class="external text external">"Corixa and Glaxo's Cancer Drug Wins F.D.A. Approval"</a>. <i>The New York Times</i>. 1 July 2003. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0362-4331  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0362-4331'" tppabs="https://www.worldcat.org/issn/0362-4331" class="external text external">0362-4331</a>.</cite>New York Times.  July 1, 2003 <a href="javascript:if(confirm('https://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html'" tppabs="https://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html" class="external text external">Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval</a></span></li><li id="cite_note-FDAapproval-8"> <span id="mw-reference-text-cite_note-FDAapproval-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/tosicor062703L.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/tosicor062703L.htm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/tosicor062703L.htm" class="external text external">"Tositumomab - Product Approval Information - Licensing Action"</a>. <i>FDA/Center for Drug Evaluation and Research</i>. 2 July 2003.</cite></span></li><li id="cite_note-2002Descrip-9"> <span id="mw-reference-text-cite_note-2002Descrip-9" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20180127032045/https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916B1_02_D-FDA%20-%20Product%20Description.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20180127032045/https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916B1_02_D-FDA%20-%20Product%20Description.htm'" tppabs="https://web.archive.org/web/20180127032045/https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916B1_02_D-FDA%20-%20Product%20Description.htm" class="external text external">"Tositumomab product description"</a>. <i>Food and Drug Administration</i>. Archived from <a href="javascript:if(confirm('https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916B1_02_D-FDA%20-%20Product%20Description.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916B1_02_D-FDA%20-%20Product%20Description.htm'" tppabs="https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916B1_02_D-FDA%20-%20Product%20Description.htm" class="external text external">the original</a> on 27 January 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">25 July</span> 2020</span>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20180125201355/https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916b1.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20180125201355/https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916b1.htm'" tppabs="https://web.archive.org/web/20180125201355/https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916b1.htm" class="external text external">"Briefing Information Iodine I-131 Tositumomab"</a>. <i>Food and Drug Administration</i>. 17 December 2002. Archived from <a href="javascript:if(confirm('https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916b1.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916b1.htm'" tppabs="https://www.fda.gov/ohrms/dockets/ac/02/briefing/3916b1.htm" class="external text external">the original</a> on 25 January 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">25 July</span> 2020</span>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.federalregister.gov/documents/2013/10/23/2013-24840/glaxosmithkline-llc-withdrawal-of-approval-of-the-indication-for-treatment-of-patients-with-relapsed  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.federalregister.gov/documents/2013/10/23/2013-24840/glaxosmithkline-llc-withdrawal-of-approval-of-the-indication-for-treatment-of-patients-with-relapsed'" tppabs="https://www.federalregister.gov/documents/2013/10/23/2013-24840/glaxosmithkline-llc-withdrawal-of-approval-of-the-indication-for-treatment-of-patients-with-relapsed" class="external text external">"GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With Relapsed or Refractory, Low Grade, Follicular, or Transformed CD20 Positive Non-Hodgkin's Lymphoma Who Have Not Received Prior Rituximab; BEXXAR"</a>. <i>Federal Register</i>. 23 October 2013.</cite> (<span>78 </span>FR<span> </span><a href="javascript:if(confirm('https://www.federalregister.gov/citation/78-FR-63226  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.federalregister.gov/citation/78-FR-63226'" tppabs="https://www.federalregister.gov/citation/78-FR-63226" class="external text external">63226</a>)</span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu303137  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu303137'" tppabs="https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu303137" class="external text external">"EU/3/03/137"</a>. <i>European Medicines Agency</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">25 July</span> 2020</span>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu303136  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu303136'" tppabs="https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu303136" class="external text external">"EU/3/03/136"</a>. <i>European Medicines Agency</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">25 July</span> 2020</span>.</cite></span></li></ol></div></div>

<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_tumors" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Monoclonal_antibodies_for_tumors" style="font-size:114%;margin:0 4em">Monoclonal antibodies for tumors</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;">Tumor<br></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Human</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Adecatumumab<sup>§</sup></li>
<li>Ascrinvacumab<sup>§</sup></li>
<li>Atezolizumab</li>
<li>Cixutumumab<sup>§</sup></li>
<li>Conatumumab<sup>§</sup></li>
<li>Daratumumab</li>
<li>Drozitumab<sup>§</sup></li>
<li>Duligotumab<sup>§</sup></li>
<li>Dusigitumab<sup>§</sup></li>
<li>Enfortumab vedotin<sup>†</sup></li>
<li>Enoticumab<sup>§</sup></li>
<li>Figitumumab<sup>§</sup></li>
<li>Ganitumab<sup>†</sup></li>
<li>Glembatumumab vedotin<sup>†</sup></li>
<li>Intetumumab<sup>§</sup></li>
<li>Ipilimumab</li>
<li>Iratumumab<sup>§</sup></li>
<li>Istiratumab</li>
<li>Icrucumab<sup>§</sup></li>
<li>Lexatumumab<sup>§</sup></li>
<li>Lucatumumab<sup>§</sup></li>
<li>Mapatumumab<sup>§</sup></li>
<li>Narnatumab<sup>§</sup></li>
<li>Necitumumab</li>
<li>Nesvacumab<sup>§</sup></li>
<li>Nivolumab<sup>#</sup></li>
<li>Ofatumumab</li>
<li>Olaratumab<sup>†</sup></li>
<li>Panitumumab</li>
<li>Patritumab<sup>§</sup></li>
<li>Pembrolizumab<sup>#</sup></li>
<li>Pritumumab<sup>§</sup></li>
<li>Radretumab<sup>§</sup></li>
<li>Ramucirumab</li>
<li>Rilotumumab<sup>†</sup></li>
<li>Robatumumab<sup>§</sup></li>
<li>Seribantumab<sup>§</sup></li>
<li>Tarextumab<sup>§</sup></li>
<li>Teprotumumab<sup>†</sup></li>
<li>Tovetumab<sup>§</sup></li>
<li>Vantictumab<sup>§</sup></li>
<li>Votumumab<sup>§</sup></li>
<li>Zalutumumab<sup>†</sup></li></ul>

<dl><dt><span class="nobold">"-melu-" (melanoma)</span></dt>
<dd>Flanvotumab<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Mouse</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Altumomab pentetate</li>
<li>Anatumomab mafenatox</li>
<li><a href="Technetium_(99mTc)_arcitumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Technetium_(99mTc)_arcitumomab" title="Technetium (99mTc) arcitumomab">Arcitumomab</a></li>
<li>Bectumomab</li>
<li>Blinatumomab</li>
<li>Detumomab</li>
<li><a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab tiuxetan</a></li>
<li>Lilotomab</li>
<li>Minretumomab</li>
<li>Mitumomab</li>
<li>Moxetumomab pasudotox</li>
<li>Naptumomab estafenatox</li>
<li>Nofetumomab merpentan</li>
<li>Pemtumomab<sup>†</sup></li>
<li>Pintumomab</li>
<li>Racotumomab</li>
<li><a href="Indium_(111In)_satumomab_pendetide.htm" tppabs="https://ptable.com/wiki/compounds/A/Indium_(111In)_satumomab_pendetide" title="Indium (111In) satumomab pendetide">Satumomab pendetide</a></li>
<li>Solitomab</li>
<li>Taplitumomab paptox</li>
<li>Tenatumomab</li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a></li>
<li>3F8</li></ul>

<dl><dt><span class="nobold">"-govo-" (ovarian tumor)</span></dt>
<dd>Abagovomab</dd>
<dd>Igovomab</dd>
<dd>Oregovomab</dd></dl>

<dl><dt><span class="nobold">"-pro-" (prostate tumor)</span></dt>
<dd>Capromab pendetide</dd></dl>

<dl><dt><span class="nobold">"-colo-" (colonic tumor)</span></dt>
<dd>Edrecolomab</dd>
<dd>Nacolomab tafenatox</dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Amatuximab<sup>§</sup></li>
<li>Bavituximab<sup>§</sup></li>
<li>Brentuximab vedotin</li>
<li>Carotuximab<sup>†</sup></li>
<li><a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Derlotuximab biotin<sup>§</sup></li>
<li>Dinutuximab</li>
<li>Ensituximab<sup>§</sup></li>
<li>Futuximab<sup>§</sup></li>
<li>Girentuximab<sup>†</sup></li>
<li>Indatuximab ravtansine<sup>§</sup></li>
<li>Isatuximab</li>
<li>Loncastuximab tesirine</li>
<li>Margetuximab<sup>†</sup></li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a><sup>#</sup></li>
<li>Siltuximab</li>
<li>Ublituximab<sup>†</sup></li>
<li>IMAB362</li></ul>

<p>"-mexi-" (melanoma): Ecromeximab<sup>§</sup></p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Humanized</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abituzumab<sup>§</sup></li>
<li><a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a></li>
<li>Belantamab mafodotin</li>
<li>Bevacizumab</li>
<li>Bivatuzumab mertansine<sup>§</sup></li>
<li>Brontictuzumab<sup>§</sup></li>
<li>Cantuzumab mertansine<sup>§</sup></li>
<li>Cantuzumab ravtansine<sup>§</sup></li>
<li>Cirmtuzumab</li>
<li>Citatuzumab bogatox<sup>§</sup></li>
<li>Clivatuzumab tetraxetan</li>
<li>Cofetuzumab pelidotin</li>
<li>Dacetuzumab<sup>§</sup></li>
<li>Demcizumab<sup>§</sup></li>
<li>Dalotuzumab<sup>§</sup></li>
<li>Denintuzumab mafodotin<sup>§</sup></li>
<li>Elotuzumab</li>
<li>Emactuzumab<sup>§</sup></li>
<li>Emibetuzumab<sup>§</sup></li>
<li>Enoblituzumab<sup>§</sup></li>
<li>Etaracizumab<sup>§</sup></li>
<li>Farletuzumab<sup>§</sup></li>
<li>Ficlatuzumab<sup>§</sup></li>
<li>Flotetuzumab<sup>§</sup></li>
<li>Gemtuzumab ozogamicin</li>
<li>Imgatuzumab<sup>§</sup></li>
<li>Inotuzumab ozogamicin<sup>†</sup></li>
<li>Labetuzumab<sup>§</sup></li>
<li>Lifastuzumab vedotin<sup>§</sup></li>
<li>Lintuzumab<sup>§</sup></li>
<li>Lorvotuzumab mertansine<sup>§</sup></li>
<li>Lumretuzumab<sup>§</sup></li>
<li>Matuzumab<sup>§</sup></li>
<li>Milatuzumab<sup>§</sup></li>
<li>Nimotuzumab<sup>†</sup></li>
<li>Obinutuzumab</li>
<li>Ocaratuzumab<sup>§</sup></li>
<li>Otlertuzumab<sup>§</sup></li>
<li>Onartuzumab<sup>§</sup></li>
<li>Oportuzumab monatox<sup>†</sup></li>
<li>Parsatuzumab<sup>§</sup></li>
<li>Pertuzumab</li>
<li>Pinatuzumab vedotin<sup>§</sup></li>
<li>Polatuzumab vedotin<sup>†</sup></li>
<li>Rosmantuzumab</li>
<li>Rovalpituzumab tesirine<sup>†</sup></li>
<li>Sacituzumab govitecan</li>
<li>Sibrotuzumab<sup>§</sup></li>
<li>Simtuzumab<sup>§</sup></li>
<li>Tacatuzumab tetraxetan<sup>§</sup></li>
<li>Tigatuzumab<sup>§</sup></li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a><sup>#</sup></li>
<li>Tucotuzumab celmoleukin<sup>§</sup></li>
<li>Vandortuzumab vedotin<sup>§</sup></li>
<li>Vanucizumab<sup>§</sup></li>
<li>Veltuzumab<sup>§</sup></li>
<li>Vorsetuzumab mafodotin<sup>§</sup></li>
<li>CBR96-doxorubicin immunoconjugate</li>
<li>PankoMab</li></ul>

<dl><dt><span class="nobold">"-gozu-" (ovarian tumor)</span></dt>
<dd>Sofituzumab vedotin<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Rat/mouse hybrid<br></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Catumaxomab</li>
<li>Ertumaxomab<sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric + humanized<br></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Depatuxizumab mafodotin<sup>†</sup></li>
<li>Duvortuxizumab</li>
<li>Ontuxizumab<sup>§</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Therapeutic_radiopharmaceuticals_(V10)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Therapeutic_radiopharmaceuticals_(V10)" style="font-size:114%;margin:0 4em">Therapeutic radiopharmaceuticals (V10)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Pain palliation</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><sup>153</sup>Sm
<ul><li>Lexidronam</li></ul></li>
<li><sup>89</sup>Sr (Strontium chloride)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Adrenergic tumors</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><sup>131</sup>I
<ul><li>Iobenguane</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">CD20 antibodies</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><sup>90</sup>Y
<ul><li><a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab tiuxetan</a></li></ul></li>
<li><sup>131</sup>I
<ul><li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Radionuclides</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">alpha emitters</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><sup>223</sup>Ra (Radium chloride)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">beta emitters</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><sup>32</sup>P</li>
<li><sup>89</sup>Sr</li>
<li><sup>90</sup>Y</li>
<li><sup>131</sup>I</li>
<li><sup>153</sup>Sm</li>
<li><sup>165</sup>Dy</li>
<li><sup>169</sup>Er</li>
<li><sup>177</sup>Lu (Oxodotreotide)</li>
<li><sup>186</sup>Re</li>
<li><sup>198</sup>Au</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>


<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>